Oncology News

SAN FRANCISCO — Starting this weekend, Healio Gastroenterology and Liver Disease will provide live coverage from The Liver Meeting 2018.

The FDA granted accelerated approval to pembrolizumab for the treatment of patients with hepatocellular carcinoma who received prior sorafenib.

Transarterial radioembolization with yttrium-90 safely and effectively treated unresectable primary malignant liver tumors in pediatric patients as an alternative therapy bridge to surgical resection or liver transplant, according to data published in Pediatric Blood and Cancer.

Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral therapy, according to a recently published study.

African-American patients presented with more advanced stages of hepatocellular carcinoma and had worse five-year survival rates compared with Caucasian patients, according to a study published in American Journal of Gastroenterology.

Liver cancer incidence and related mortality rates have been increasing significantly in the United States over the last 15 years, following increasing trends in obesity, nonalcoholic fatty liver disease and alcohol use.

LSK BioPharma and Jiangsu Hengrui Medicine announced a clinical collaborative effort to evaluate the safety and efficacy of a combination therapy for patients with advanced hepatocellular carcinoma, according to a press release.

This year at the American College of Gastroenterology Annual Meeting, several hepatology specialists discussed the changing landscape of liver disease health care, such as increasing rates of nonalcoholic fatty liver disease which is quickly becoming the number one indication for liver transplantation.

A team of physicians from the Baylor College of Medicine and the Texas Children’s Cancer Center’s Pediatric Liver Tumor Program have begun using a state-of-the-art treatment known as transarterial radioembolization to treat children with liver tumors, according to a press release.

Regular use of aspirin at specific doses appeared to decreased risk for ovarian cancer and hepatocellular carcinoma, according to two separate studies of health professionals.